Mankind Pharma profit jumps 30% on chronic therapy demand in Q4
Published on: May 20, 2026, 1:23 a.m. | Source: The Economic Times
Mankind Pharma announced a significant 30 percent profit increase for the fourth quarter. This growth was fueled by strong demand for chronic therapies and consumer healthcare products. The company's domestic formulations business is showing a revival. Improved sales execution and the successful integration of Bharat Serums and Vaccines contributed to this positive performance.
